Jaguar Health (JAGX) announced that an article about Canalevia-CA1, Jaguar’s prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, has been published in PetVet Magazine. Canalevia-CA1 is conditionally approved by the U.S. Food and Drug Administration for the treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any approval from the FDA. “As the article states, whether a patient has two legs or four, cancer therapy-related diarrhea can have a significant effect on morbidity and mortality. In human patients, managing CTD may require dosing holidays, dose reductions or discontinuations of cancer drugs, potentially resulting in less effective cancer treatment, treatment resistance or failures,” said Lisa Conte, Jaguar’s president and CEO. “Jaguar is deeply committed to supporting the quality of life of people and animals undergoing cancer treatment.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JAGX:
- Jaguar Health seeking partner to develop, commercialize NP300
- Jaguar Health Sees Revenue Growth with New Product Launches
- Jaguar Health reports Q3 EPS ($1.05) vs. ($22.50) last year
- JAGX Earnings this Week: How Will it Perform?
- Jaguar Health announces FDA approval of renewal of Canalevia-CA1
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
